532 results about "Human plasma" patented technology

The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification methods. The method of immunoaffinity purification of the invention is based on the discovery of a method for identifying antibodies that specifically bind native hpHAse (anti-native hpHAse antibodies), and anti-native hpHAse antibodies identified by this screening method. The invention also features an assay for sensitive detection of HAse activity using biotinylated hyaluronic acid (bHA). Purification and characterization of hpHAse lead to the inventors' additional discovery that hpHAse is encoded by the LuCa-1 gene, which gene is present in the human chromosome at 3p21.3, a region associated with tumor suppression. The invention additionally features methods of treating tumor-bearing patients by administration of hpHAse and/or transformation of cells with hpHAse-encoding DNA.

An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to effect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA. IgA and IgM may be eluted from these resins in high yield and purity.

Single unit human plasma is dispensed from a source transfer bag into a receptacle in which the plasma under goes freeze-drying. During the dispensing of the plasma from the source transfer container into the freeze-drying receptacle, an inline treatment device treats the plasma prior to freeze-drying, e.g., by the removal of cellular blood components, or by the removal of pathogens or viral or bacterial agents, or by the removal or neutralization of blood group specific antibodies.

Purification of α-1 proteinase inhibitor (α-1 PI) from solutions comprising α-1 PI is accomplished using hydrophobic interaction chromatography (HIC). In some embodiments, purification of α-1 PI is accomplished by precipitation of contaminating proteins from a starting solution comprising α-1 PI, such as human plasma, followed by anion exchange resin chromatography prior to HIC. Further purification may be accomplished by an optional cation exchange chromatography subsequent to anion exchange chromatography but prior to HIC. Some embodiments of the invention also include virus removal and/or inactivation by methods such as nano filtration and such as contact with a non-ionic detergent. The methods of the present invention result in greater yield, purity, and pathogenic clearance of plasma fractions than known methods.

The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.

The invention relates to the cell culture technical field, and particularly relates to a natural killer cell culture medium and a natural killer cell amplification culture method. The invention provides the culture medium used for amplification culture of natural killer cells and containing a serum-free culture medium, human plasma, IL-2, IL-21, IL-15 and OKT-3. The culture medium provided by the invention is used for amplification culture of the natural killer cells, can avoid risks caused by exogenous serum, has high amplification efficiency and allows the obtained natural killer cells to have high purity. With adopting the method for amplification of the natural killer cells, amplification of the natural killer cells can be maintained at a logarithmic phase for a longer period of time. Moreover, the cultured natural killer cells have good killing activity on tumor cells.

After many decades, 1-Naphthylisocyanate (NIC) has been identified as the most ideal pre column derivatization fluorescent tag for reversed phase Liquid Chromatographic (HPLC) analysis of all free amino acids (AA) in biological samples. NIC forms very stable derivatives with all AAs in one minute. Using NIC, the first, most simple, robust, sensitive (femto mole), and economical high pressure binary gradient, HPLC method, has been developed. It estimates 35 (and 2 internal standards) AAs in human plasma in record shortest time of 20 minutes and has been validated for precision (n=16, <6%), accuracy 95 %, linearity (0 to 1200 μM/L), and analyzing normal and abnormal patients. It can provide with in 20 minutes the first and best plasma free AAs profile that includes Homocysteine, Cysteine, Alloisoleucine, and Cystathionine and a 27 AAs profile using a blood spot (3 μl plasma). A sample can be analyzed with in one hour of its arrival in the laboratory.

The invention provides a clinic freeze-preservation protective solution composition for umbilical cord mesenchymal stem cells and application thereof. The protective solution composition comprises the following components: compound dextranum 40 injection, human serum albumin and DMSO. Compared with the prior art, the composition has the beneficial effects that the clinic freeze-preservation protective solution for umbilical cord mesenchymal stem cells can main the activity and biology activity of the mesenchymal stem cell for a long time, and does not contain unsafe components such as cell culture mediums, fetal calf serum and human plasma. All ingredients comprise clinical drug compound dextranum 40 injection, 20% human serum albumin or clinically used (dimethyl sulfoxide (UPS clinical level)), and the stability of the clinically standardized mesenchymal stem cell freeze-preservation system can be guaranteed while the umbilical cord mesenchymal stem cells for cryopreservation resuscitation meet the clinic using requirement. The application is safe, effective and simple in preparation method, and has good clinical application prospect.

The invention relates to a D-dimer quantitative fluorescence immunoassay test strip. The test strip comprises a sample pad, a bind pad, a nitrocellulose film and absorbent paper, wherein the sample pad is a two-layer sample pad; the bind pad is coated with a fluorescence latex microsphere marked anti D-dimer antibody A; the nitrocellulose film is coated with an anti D-dimer antibody B serving as an assay line and a rabbit antimouse IgG antibody serving as a control line; and the fluorescence late microsphere is prepared from latex microsphere adsorptive fluorescence marked streptavidin. The test strip can be used for accurately and quantitatively assaying the content of D-dimer in human blood plasma, and has the characteristics of convenience in operation, high accuracy, high sensitivity, low cost and the like.

The invention discloses a preparation method for human immunoglobulin for intravenous injection. The preparation method comprises the following steps: (1) two-step filtering pressing: separating II+III precipitate from human plasma as a starting raw material, removing component III precipitate through low-temperature ethanol filter pressing, collecting supernatant, performing ultrafiltration and dialysis to the supernatant, and regulating the protein concentration; (2) two-step chromatography: performing upper column chromatography purification through a DEAF-Sepharose-FF ion exchange column, and collecting a first-step flow penetration liquid; performing ultrafiltration and dialysis to the collected first-step flow penetration liquid, regulating and performing chromatographic purification by using a Fractogel-EMD-TMA ion exchange column, and collecting a second-step flow penetration liquid; (3) performing ultrafiltration, dialysis and liquid preparation to the collected second-step flow penetration liquid; (4) inactivating virus, disinfecting, filtering and subpackaging to obtain a product. The product prepared by using the method is higher in bioactivity, yield and purity.

A preparation method of tumor labeled substance quality control belongs to the biological product technical field and comprises the following steps: after being added calcium chloride solution, the finished product human plasma is hatched for 1-3 hours in 36-38 DEG C and is centrifugalized at the speed of 3500-4500 r/m; after fiber protein in the plasma is eliminated, the plasma becomes quality control serum metrix; after being added tumor labeled substance quality control specimen in a certain scope of contents, the quality control serum metrix becomes the crude product of quality control product; after being added antiseptic and mixed uniformly, the quality control crude product is fractionally packed, dried in vacuum and low temperature and determined. The preparation method of tumor labeled substance quality control adopts the finished product human plasma which has adequate source and is easy to obtained as material; after the plasma is processed, the ingredients of organic substance in the plasma is totally identical with the ingredients of serum, which not only guarantees the quantity and the quality of quality control product but also has the advantages of less additive, less modulated substance, small vial to vial difference, a full set of quality control detecting projects, low production cost and long period of validity; furthermore, a lyophilizing reagent has sound stability after being reconstituted.

The invention relates to the field of medical biotechnology, in particular to a making method for coronary heart disease and apoplexy risk diagnosis kit. The kit is used for quantitative analysis of Lp-PLA2 level in human plasma or blood serum by enzyme linked immunosorbent assay, so as to prevent heart disease and apoplexy.

The invention discloses a detection method for high throughput liquid chromatogram tandem mass spectrum. The method comprises the following steps: (S1) preparing a sample; (S2) performing derivatization reaction; (S3) pretreating the sample; (S4) separating the liquid chromatogram; and (S5) detecting the tandem mass spectrum. Besides, the invention also discloses a method for detecting four catecholamine metabolites through a high throughput liquid chromatogram tandem mass spectrometry. The detection method provided by the invention is fit for the detection for the catecholamine metabolites in human plasma and has the advantages of simple sample pretreatment, capability of simultaneously detecting four catecholamine metabolites, excellent detection specificity, short time in the whole detection process and high throughput.

A method of making a bioplastic, and a bioplastic produced thereby, by using human plasma in which human plasma is clotted, either dried through its gel phase or dried and powdered, and processed into a bioplastic with the addition of at least one plasticizer followed by forming and heating to form a final bioplastic construct.